British biotech behind bloodstream tests for cancer strikes cope with German drugs giant

A British biotech minnow developing bloodstream tests to identify cancer has struck a sales cope with a German ­genetics giant indexed by New You are able to it hopes will unlock accessibility lucrative US market.

Position, that is for auction on London’s junior market Aim, has sealed a tie-track of Qiagen, a strong with $1.34bn (£1.01bn) of revenues this past year.

Qiagen, also indexed by Frankfurt, is almost 3,000 occasions the size of Position, which in fact had sales of just £361,000.

Position hopes the offer, which provides it use of Qiagen’s subscriber base in excess of 500,000, would be the to begin many with big pharma because it looks to commercialise its technology.

“It’s a significant advance for all of us,Inches stated Andrew Newland, leader at Position. “We wish to partner with as numerous large companies as possible.Inches

The co-marketing agreement will initially concentrate on bloodstream tests to assist ­determine cancer indications and then any relevant genetic traits in prostate and cancer of the breast patients.

Ultimately Position wishes to develop bloodstream tests that may catch the first indications of cancer in patients exhibiting limited or no signs and symptoms.

Analysts expect Position to develop substantially as health services and drug firms turn to match modern-day drugs with better diagnostic tools. Mr Newland added: “Developing better diagnostic tools is important towards saving on healthcare bills.”

How you can interact with us Telegraph Business on social networking

Leave a Reply

Your email address will not be published. Required fields are marked *